Research & Development: Page
-
PharmaVoice Team/PharmaVoice
Last Word
Pfizer’s Mark Swindell discusses the integration of Wyeth’s vaccine business after the acquisition by Pfizer. As President of Vaccines, Mr. Swindell is helping to create a seamless process for melding the former Wyeth specialty business with Pfizer. One of the stated goals for the combined Pfize...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL John DUCKER, APP Pharmaceuticals Dr. Julie GERBERDING, Merck Dr. Michael ROSENBLATT, Merck Sean NOLAN, Lundbeck Inc. Derica RICE, Lilly Biotechnology POOL Dr. Mark BAGARAZZI, Inovio Biomedical Hans BISHOP, Dendreon Suzanne CADDEN, ImmunoGen Dr. Thomas HOFSTAETTER, VaxInnate Dr...
By PharmaVoice Team • March 4, 2010 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Perceptive Informatics Introduces E-Clinical Suite Elsevier Launches Online Resource Center for ARRA Updates Thomson Pharma Database Integrates Trial Protocol, Outcome Info Take Supply Chain Releases Multi-Tenant ...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: GxP Consulting Adds Statistical Analysis Support Former Wyeth VP Launches Petkus Communications Consultants GlobalHealth Provides Corporate Training, Degree Programs Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuro...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Process Inefficiencies Cause $11 Billion in Annual Pharma Revenue Leakage Sidebar: Key Findings of Revenue Leakage Study Drug Companies Still Under Pressure to Increase Pace of Development Sidebar: Key Near-Term Trends i...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
As PharmaVOICE enters its 10th year, the basic premise on which we founded the publication, and the company, remains as true today as it did on that February afternoon back in 2001: there is a fundamental need to understand the life-sciences industry from a holistic perspective that cuts across i...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Last Word
Rewarding Performance Procter & Gamble is a recognized leader in consumer goods marketing. What, if any, learnings from the consumer-goods side of the business did the Prilosec OTC brand team employ in developing this program? Cleveland: Procter & Gamble and the Prilosec OTC new sponsor...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Paul LAMMERS Mirna Appoints Chief Executive Mirna Therapeutics has named Paul Lammers, M.D., president and CEO. As head of Mirna, Dr. Lammers is responsible for driving the company’s discoveries in the field of microRNA (miRNA) into the clinic. Dr. Lammers was previously pr...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: IntraLinks, Adobe Collaborate on Data-Capture Solutions for Clinical Trials Maestro eLearning Creates e-Learning Library Deloitte Recap Helps Biopharma Executives Make Portfolio Decisions Thomson Reuters Unveil...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Companies Advised to Communicate with Payers Earlier in Drug Development Sidebar: Average Allocation of a Managed Markets Department’s Personnel Pharma Companies Add Employer Market to the Mix Sidebar: Employer Programs...
By PharmaVoice Team • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In our lifetime… There are few, if any, of us who can say we have been lucky enough to escape the ravaging effects of cancer — be it ourselves, a significant other, family member, or friend. For more years than I care to remember, “a cure for cancer" has been just around the corner. Recently, Pre...
By Taren Grom • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Dr. Alan E. Guttmacher — In the genes
AS THE RECENTLY APPOINTED SECOND DEPUTY DIRECTOR OF THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE,THE INSTITUTION RESPONSIBLE FOR LEADING THE HUMAN GENOME PROJECT, DR.ALAN GUTTMACHER’S EXTENSIVE CLINICAL GENETICS BACKGROUND WILL BE INVALUABLE AT A TIME WHEN RESEARCHERS ARE BEGINNING TO TRANSLATE T...
By Kim Ribbink • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
The Package Deal
PharmaVOICE Container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or device, or any likeness thereof, of a drug manufacturer, pro cessor, packer, or distributor other than the per son or persons who in fact manufactured, pro ce...
By Elizabeth Pena • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
E-Media
E-MEDIA NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES FDAnews has launched Drug Industry Daily, an electronic daily publication that provides news coverage of what’s happening on Capitol Hill, in the courts, and at the Food and Drug Administration, the Federal Trade Commission...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Doctors+Designers has changed its company name to HealthEd to reflect a change in business strategy focusing on developing patient-centered health education programs. “With noncompliance costing the pharmaceuti cal industry $15 billion to $2...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY NestEggz Survey Suggests PATIENTS WHO SAVE ON PRESCRIPTIONS TAKE THEIR MEDICATION Almost 90% of cholesterol patients enrolled in NestEggz were found to take their medication daily, almost double the national average.NestEggz,a...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Dr. Jon Adler — Medicine Man
Man FROM THE EMERGENCY ROOM TO THE BOARDROOM, Jonathan N. Adler, M.D., is committed to the practice of medicine. As a physician, lecturer, and president and chief medical officer of eMedicine, he balances all endeavors with one goal in mind: fostering better medicine. BY KIM RIBBINK JON Adler Pha...
By Kim Ribbink • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Pushing Past the Paper
PharmaVOICE W While adoption of a paperless approach by pharmaceutical companies has been gradual, Forrester Research, based on a recent survey of 400 pharmaceutical profession als, is projecting that 24% of all new clinical trials will be Web enabled by 2004. Integrated electronic applica tion, ...
By Taren Grom • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
NEUROTHERAPEUTICS AND GENE AMPLIFICATION Markets Predicted to Grow Unmet need and ballooning incidence are expected to create huge market potential in neuro logical drugs,according to a study by Kalorama Infor mation. The world market stands at $70 billion, but steady growth in demand and product...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
Fewer new drug approvals, the political spotlight on the pharmaceutical industry, promotional budget cutbacks. What else can go wrong in the healthcare communications industry? Pitted against their more endowed competitors, small agencies may be wellsuited to survive in today’s adverse environmen...
By Rico Viray • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
What's on your mind: Opinions
R&D will tell I am not sure that the mega company strategy/structure will support the trend toward biopharmaceutical products (and fur ther into the future, gene therapies) that offer therapeutic solutions for more specific diseases. The trend toward blockbuster product launches will give way...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
John T. Spitznagel — A New Horizon
PharmaVOICE EARLY ON IN HIS CAREER,JOHN SPITZNAGEL SET HIS SIGHTS ON ONE DAY RUNNING A HEALTHCARE COMPANY. IN MAY 2002, AS CHAIRMAN AND CEO OF ESP PHARMA, HIS VISION BECAMEAREALITYONCEAGAIN. Mr. Spitznagel already has proven that he has what it takes to drive a company to success, having engineer...
By Kim Ribbink • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Finding a Spot for Frova
Instead of trying to conquer the entire antimigraine market, Frova will stake its claim by focusing on a niche market segment that can benefit from the drug’s unique halflife and superior safety profile Frova isn’t the drug for every migraine patient. The marketers of the latest triptan to enter ...
By Elisabeth Pena • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Manufacturing for Bio Capacity
George Coleman President, Biomedex Inc., Spokane, Wash.; Biomedex specializes in a broad spectrum of contract manufacturing services for bio- pharmaceutical clients, from regulatory compliance to aseptic filling, to validation, to cleanroom sanitizing agents, to quality assurance, to component cl...
By Denise Myshko • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARE RELATED PRODUCTS, SERVICES, AND COMPANIES Dorland Sweeney Jones Health Communications is reaffirming its position as a leader in global health communications and creating a power brand by simplifying its name and organizational structure. The agency has returned to its original nam...
By PharmaVoice Team • Jan. 11, 2010
Previous
